|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500098399 |
|
最近更新日期: Date of Last Refreshed on: |
2025-03-07 08:55:12 |
|
注册时间: Date of Registration: |
2025-03-07 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
移植后肠道微生物组分变化与移植相关并发症发生:一项前瞻性观察性研究 |
|
Public title: |
Post-Transplant Alterations in the Intestinal Microbiota and the Incidence of Transplant-Associated Complications: A Prospective Observational Investigation |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
移植后肠道微生物组分变化与移植相关并发症发生:一项前瞻性观察性研究 |
|
Scientific title: |
Post-Transplant Alterations in the Intestinal Microbiota and the Incidence of Transplant-Associated Complications: A Prospective Observational Investigation |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
王相 |
研究负责人: |
张曦 |
|
Applicant: |
Xiang Wang |
Study leader: |
Xi Zhang |
|
申请注册联系人电话: Applicant telephone: |
+86 159 0612 9020 |
研究负责人电话: Study leader's telephone: |
+86 138 0831 0064 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1132362381@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
zhangxxi@sina.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国重庆市沙坪坝区新桥街道183号 |
研究负责人通讯地址: |
中国重庆市沙坪坝区新桥街道183号 |
|
Applicant address: |
183 Xinqiao Street, Shapingba District, Chongqing |
Study leader's address: |
183 Xinqiao Street, Shapingba District, Chongqing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
陆军军医大学第二附属医院 |
||
|
Applicant's institution: |
The Second Affiliated Hospital of Army Medical University |
||
|
研究负责人所在单位: |
陆军军医大学第二附属医院 |
||
|
Affiliation of the Leader: |
The Second Affiliated Hospital of Army Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024-研第 313-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军陆军军医大学第二附属医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of second Affiliated Hospital of Army Medical University, PLA |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-12-16 00:00:00 |
||
|
伦理委员会联系人: |
胡岚岚 |
||
|
Contact Name of the ethic committee: |
Lanlan Hu |
||
|
伦理委员会联系地址: |
重庆市沙坪坝区新桥街道183号 |
||
|
Contact Address of the ethic committee: |
183 Xinqiao Street, Shapingba District, Chongqing |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 23 6875 5422 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
陆军军医大学第二附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Affiliated Hospital of Army Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国重庆市沙坪坝区新桥街道183号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
183 Xinqiao Street, Shapingba District, Chongqing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
造血干细胞移植转化研究创新群体(cstc2021jcyj-cxttX0001) |
||||||||||||||||||||||
|
Source(s) of funding: |
Innovative Group for Translational Research in Hematopoietic Stem Cell Transplantation(cstc2021jcyj-cxttX0001) |
||||||||||||||||||||||
|
Target disease: |
Graft Versus Host Disease |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
本项目拟探索异基因造血干细胞移植患者术后肠道微生物组分变化与移植并发症(植入失败与植入不良、胃肠道急性及慢性GVHD、胃肠道感染)之间的关系。 |
||||||||||||||||||||||
|
Objectives of Study: |
This project aims to explore the relationship between postoperative changes in the gut microbiome of allogeneic hematopoietic stem cell transplantation patients and transplantation complications (engraftment failure and poor engraftment, acute and chronic gastrointestinal GVHD, and gastrointestinal infections). |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)2024年12月-2027年12月,本中心≤65岁,异基因造血干细胞移植患者;(2)患者近三年居住在西南地区 (重庆、四川、贵州、云南);(3)自愿参与本研究,并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
(1) From December 2024 to December 2027, patients undergoing allogeneic hematopoietic stem cell transplantation at this center who are <=65 years old; (2) Patients who have resided in the Southwest region (Chongqing, Sichuan, Guizhou, Yunnan) for the past three years; (3) Patients who voluntarily participate in this study and sign an informed consent form. |
||||||||||||||||||||||
|
排除标准: |
(1)排除患有炎症性肠病、肠易激综合征或胃肠道恶性肿瘤患者;(2)排除传染病如HIV、梅毒;(3)排除存在肠道手术病史患者;(4)排除妊娠、哺乳期女性;(5)其他任何研究者认为不适合入组该研究的情况。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Exclude patients with inflammatory bowel disease, irritable bowel syndrome, or gastrointestinal malignant tumors; (2) Exclude patients with infectious diseases such as HIV, syphilis; (3) Exclude patients with a history of intestinal surgery; (4) Exclude pregnant and lactating women; (5) Exclude any other situations that the researcher deems unsuitable for inclusion in the study. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-04-01 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2025-04-01 00:00:00 至 To 2026-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
原始数据于试验结束6个月内采用临床试验公共管理平台向公众开放查询,http://www.medresman.org |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The raw data will open to the public with management platform in the 6 months after clinical trials finished, http://www.medresman.org |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
原始数据采用临床试验公共平台进行记录和管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
The raw data will record and manage by the public management platform of clinical trials. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |